Mochida Pharmaceutical Co. Ltd

Research Mochida Pharmaceutical Co. Ltd (MFY) on Bullrun: market cap EUR 606.67M, P/E 14.3, dividend yield 2.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 606.67M; P/E is 14.3; dividend yield is 2.5%.

Peer valuation comparison

Latest P/E is 14.33x versus a Healthcare sector median of 24.46x (41.4% below).

Latest dividend yield is 2.54% versus a Healthcare sector median of 2.11% (20.4% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026JPY 116.95BJPY 7.90B-JPY 10.05B48.1%222.96JPY 28.06BJPY 10.00BJPY 140.32B
FY2025JPY 105.16BJPY 5.69BJPY 7.19B51.1%160.36JPY 45.15Bn/aJPY 130.69B
FY2024JPY 102.89BJPY 4.55B-JPY 9.78B50.6%126.8JPY 33.29Bn/aJPY 127.97B
FY2023JPY 103.26BJPY 6.65BJPY 5.13B53.4%178.93JPY 47.01Bn/aJPY 126.77B
FY2022JPY 110.18BJPY 10.57BJPY 4.36B54.1%277.39JPY 48.42Bn/aJPY 128.64B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23EUR 606.67M14.32.7%0.46

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.46 EUR, yield 2.5%.

YearDividends/share
FY20260.22 JPY
FY20250.43 JPY
FY20240.43 JPY
FY20230.43 JPY
FY20220.49 JPY

About Mochida Pharmaceutical Co. Ltd

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Mochida Pharmaceutical Co. Ltd's market cap?

Mochida Pharmaceutical Co. Ltd's market capitalization is EUR 606.67M.

What is Mochida Pharmaceutical Co. Ltd's P/E ratio?

Mochida Pharmaceutical Co. Ltd's price-to-earnings (P/E) ratio is 14.3.

Does Mochida Pharmaceutical Co. Ltd pay a dividend?

Mochida Pharmaceutical Co. Ltd has a dividend yield of 2.5%.

What does Mochida Pharmaceutical Co. Ltd do?

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with.